Publications by authors named "A Esquenazi"
Background: Spasticity is a common feature in patients with disruptions in corticospinal pathways. However, the term is used ambiguously. Here, spasticity is defined as enhanced velocity-dependent stretch reflexes and placed within the context of deforming spastic paresis encompassing other forms of muscle overactivity.
View Article and Find Full Text PDFObjective: To assess longitudinal goal attainment with repeat abobotulinumtoxinA (AboBoNT-A) injections for lower limb spasticity (LLS) over 16 months.
Design: Prospective, longitudinal, international, multicenter, observational study (NCT04050527).
Setting: Specialist neurorehabilitation centers.
Article Synopsis
- Upper and lower limb spasticity often occurs with central nervous system disorders, but there's limited knowledge on treating both limbs with botulinum toxins.
- The study aimed to assess the use of onabotulinumtoxinA (onabotA) and its effects on spasticity in limbs, based on data gathered from an international registry over two years.
- Results showed significant participant and physician satisfaction, along with improvements in pain, disability, and quality of life after onabotA treatment, although a small percentage reported adverse effects.
Article Synopsis
- - The study aimed to assess the safety of onabotulinumtoxinA for treating spasticity in real-world settings over two years, analyzing various dose ranges.
- - Data was collected from 3,103 treatment sessions involving 730 patients, categorizing adverse events and serious adverse events based on cumulative dosage given per session.
- - Most patients received doses of 201-400 U, with no new safety concerns identified; the adverse event profile was consistent with existing global safety information for the treatment.